The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug

The head of the FDA is calling for an investigation into her agency's controversial decision to approve a new Alzheimer's drug

Business Insider

Published

The decision to approve Aduhelm has raised concerns and led three advisors to resign. The agency's head is now asking for an outside investigation.

Full Article